Business Wire - November 05, 2009
PARIS - Regulatory News: Results on epidemiologic study on OroPharyngeal Candidiasis (OPC) in oncology were presented at the 51st ASTRO (American Society for Therapeutic Radiology and Oncology) Meeting in Chicago (From November 1st to November 5th).
Pr David Azria (Anticancer Center Montpellier) has presented the data collected in 35 public and private oncology centers.
This study of 2027 cancer patients revealed a 10% prevalence (total number of cases of a disease in a given population at a specific time) of OPC. Patients receiving a combination of chemotherapy and radiotherapy are more likely to suffer from OPC (22%) than those receiving chemotherapy or radiotherapy alone. Highest prevalence was seen in patients with head and neck cancer (30%). Local treatments, such as miconazole MBT, amphotericin B or nystatin mouthwashes are usually prescribed, as per treatment guidelines. Treatment compliance is strongly increased with drugs administered once daily (miconazole MBT) versus treatments with multiple daily dosing (amphotericin B or nystatin mouthwashes).
* miconazole MBT: Mucoadhesive Buccal Tablet, Loramyc(R) in Europe
About OPC
Also known as thrush is an oral fungal infection most common in individuals with weakened immune systems - particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, burning and/or altered taste.
About ASTRO
Radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists and biologists comprise ASTRO's more than 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals and cancer treatment centers around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. These teams, which often include a nutritionist and a social worker, treat more than 1 million cancer patients each year.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma (Paris:BIO) is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.
For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).
Contacts
BioAlliance Pharma SA
Dominique Costantini MD, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
091105
BW091106
Copyright © 2009 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .